How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,971 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Breastfeeding, HIV exposure, childhood obesity, and prehypertension: A South African cohort study. (Full text)

was independently associated with reduced childhood obesity for both HIV-exposed and unexposed children, suggesting that promoting optimal nutrition throughout the life course, starting with continued breastfeeding, may be critical to tackling the growing obesity epidemic. In the era of widespread effective antiretroviral treatment for HIV-infected women for life, these data further support the recommendation of breastfeeding for all women. (...) Breastfeeding, HIV exposure, childhood obesity, and prehypertension: A South African cohort study. Evidence on the association between breastfeeding and later childhood obesity and blood pressure (BP) is inconsistent, especially in HIV-prevalent areas where, until recently, HIV-infected women were discouraged from breastfeeding, but obesity is increasingly prevalent.The Siyakhula cohort (2012-2014), a population-based prospective cohort study, collected data over 3 visits on HIV-negative

2019 PLoS medicine

202. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya. (Full text)

Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya. The World Health Organization recommends "same-day" initiation of antiretroviral therapy (ART) for HIV patients who are eligible and ready. Identifying efficient, safe, and feasible procedures for determining same-day eligibility and readiness is now a priority. The Simplified Algorithm for Treatment Eligibility (...) (SLATE) study evaluated a clinical algorithm that allows healthcare workers to determine eligibility for same-day treatment and to initiate ART at the patient's first clinic visit.SLATE was an individually randomized trial at three outpatient clinics in urban settlements in Johannesburg, South Africa and three hospital clinics in western Kenya. Adult, nonpregnant, HIV-positive, ambulatory patients presenting for any HIV care, including HIV testing, but not yet on ART were enrolled and randomized

2019 PLoS medicine

203. Follicular helper T cells are major HIV-2 reservoirs and support productive infection. (Full text)

Follicular helper T cells are major HIV-2 reservoirs and support productive infection. Follicular helper T cells (Tfh), CD4 lymphocytes critical for efficient antibody responses, have been shown to be key HIV-1 reservoirs. HIV-2 infection represents a unique naturally-occurring model for investigating Tfh role in HIV/AIDS, given its slow rate of CD4 decline, low to undetectable viremia and high neutralizing antibodies titers throughout the disease course. We investigated here, for the first (...) time, Tfh susceptibility to HIV-2 infection by combining in vitro infection of tonsillar Tfh with the ex vivo study of circulating Tfh from HIV-2-infected patients. We reveal that Tfh support productive HIV-2 infection and are preferential viral targets in HIV-2-infected individuals.© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

2019 Journal of Infectious Diseases

204. An Association between Hidradenitis Suppurativa and HIV. (PubMed)

An Association between Hidradenitis Suppurativa and HIV. Hidradenitis suppurativa (HS) is a chronic inflammatory disorder of hair follicles in the apocrine gland-bearing areas of the body, characterized by inflamed nodules, recurrent abscesses, mucopurulent discharge, and subsequent scarring. A few case reports have described the atypical manifestations, clinical course, and therapeutic challenges of HS in patients with HIV.1,2 However, the relationship between the two has not been explored (...) previously to our knowledge. Our aim was to investigate the association between HS and HIV in the United States. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

205. Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD). (PubMed)

Rationale and design of a nurse-led intervention to extend the HIV treatment cascade for cardiovascular disease prevention trial (EXTRA-CVD). Persons living with human immunodeficiency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD). In spite of this, uptake of evidence-based clinical interventions for ASCVD risk reduction in the HIV clinic setting is sub-optimal. METHODS: EXTRA-CVD is a 12-month randomized clinical effectiveness trial that will assess (...) will be change in systolic blood pressure and secondary outcome will be change in non-HDL cholesterol over the course of the intervention. Tertiary outcomes will include change in the proportion of participants in the following extended cascade categories: (1) appropriately diagnosed with hypertension and hyperlipidemia (2) appropriately managed; (3) at treatment goal (systolic blood pressure <130 mm Hg and non-HDL cholesterol < National Lipid Association targets). CONCLUSIONS: The EXTRA-CVD trial

2019 American Heart Journal Controlled trial quality: uncertain

206. Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART. (PubMed)

Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART. TB is the leading cause of death among HIV-infected children, yet treatment options for those who require PI-based ART are suboptimal. Rifabutin is the preferred rifamycin for adults on PI-based ART; only one study has evaluated its use among children on PIs and two of six children developed treatment-limiting neutropenia.Since 2009, rifabutin has been available for HIV/TB-coinfected children (...) requiring PI-based ART in the Harvard/APIN programme in Nigeria. We retrospectively analysed laboratory and clinical toxicities at baseline and during rifabutin therapy, and examined HIV/TB outcomes.Between 2009 and 2015, 48 children received rifabutin-containing TB therapy with PI (lopinavir/ritonavir)-based ART: 50% were female with a median (IQR) baseline age of 1.7 (0.9-5.0) years and a median (IQR) CD4+ cell percentage of 15% (9%-25%); 52% were ART experienced. Eighty-five percent completed the 6

2019 Journal of Antimicrobial Chemotherapy

207. Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network. (PubMed)

interruption.Treatment with PD-1 inhibitors seems to have an efficacy signal and be well tolerated in PLWHIV, including impact on CD4 lymphocyte count and HIV load, that should be monitored during treatment course (regarding real-life experience). (...) Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience on behalf of the French CANCERVIH network. To report efficacy and tolerance of nivolumab or pembrolizumab, PD-1 inhibitors, in people living with HIV (PLWHIV) and cancer.Series of PLWHIV cancer patients treated with anti-PD1 agents in real life clinical practice.From May 2014 to January 2019, 575 HIV infected patients have been discussed in the French CANCERVIH national

2019 AIDS

208. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. (Full text)

the primary outcome of a sustained virologic response 12 weeks after the date of the last dose of study treatment (90% confidence interval 90-100%), achieving non-inferiority versus the 60% historic benchmark. No treatment discontinuations occurred.This multicenter clinical trial, investigating 8 weeks of ledipasvir/sofosbuvir for acute HCV infections in men with HIV infections, reports a 100% SVR. This study provides the rationale for larger studies of shortened courses of direct-acting antiviral (...) Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Current guidelines for the management of hepatitis C virus (HCV) infections provide varying recommendations for the optimal treatment of acute HCV infections. There are limited data from small cohort studies to provide guidance on the best approach

2019 Clinical Infectious Diseases

209. Topical treatments for HIV-related oral ulcers. (PubMed)

Topical treatments for HIV-related oral ulcers. In HIV-infected adults, oral ulcers occur more frequently, last longer and produce more painful symptoms than in immunocompetent people. Oral aphthous ulcers observed during the course of HIV infection may be severe and can result in significant morbidity in these patients. Such manifestations may interfere with oral functions and alter patients' quality of life.To evaluate the efficacy and side effects of topical agents used in the treatment (...) of HIV-related oral aphthous ulcers in adults.The following electronic databases were searched from the year 1980 to May 2011 for randomised controlled trials involving managements of oral ulcers, apthouses in HIV infected adults: EMBASE, PUBMED, the Cochrane Central Register of Controlled Trials (CENTRAL).Only randomised controlled trials that evaluated the efficacy of any topical agent in treating HIV oral aphthous ulcerations in HIV positive adults were considered.Two authors independently

2012 Cochrane

210. Management of HIV-exposed and HIV-infected children

Management of HIV-exposed and HIV-infected children Management of HIV-exposed and HIV-infected children | Canadian Paediatric Society CPS In this section Protecting and promoting the health and well-being of children and youth CPS Policy & Advocacy Clinical Practice Education & Events News & Publications Programs Membership About the CPS Practice Point Management of HIV-exposed and HIV-infected children Posted: Aug 1 2010 | Reaffirmed: Feb 28 2018 The Canadian Paediatric Society gives (...) permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) JL Robinson; Canadian Paediatric Society, Paediatr Child Health 2010;15(6):379 The management of HIV-exposed and HIV-infected children has been improved by the introduction of new testing methods and of new antiretroviral agents. Whenever practical, such children should be cared for in consultation with paediatric infectious disease physicians

2010 Canadian Paediatric Society

211. Recipient Assessment for Transplantation - HIV, HBV and HCV infection

Recipient Assessment for Transplantation - HIV, HBV and HCV infection ________________________________________________________________________________________________________________________ Recipient Assessment for Transplantation March 2013 Page 1 of 23 HIV, HBV and HCV infection Date written: November 2011 Author: David Gracey GUIDELINES a. Human immunodeficiency virus (HIV) We recommend that HIV infection should not preclude a patient from being assessed for kidney transplantation (Level 1D (...) ) b. Hepatitis B virus (HBV) We recommend that HBV infection should not preclude a patient from being assessed for kidney transplantation (Level 1D) c. Hepatitis C virus (HCV) We recommend that HCV infection should not preclude a patient from being assessed for kidney transplantation (Level 1D) UNGRADED SUGGESTIONS FOR CLINICAL CARE HIV Testing for HIV should be performed in all potential kidney transplant candidates (ungraded) Assessment of HIV-infected potential kidney transplant patients should

2013 KHA-CARI Guidelines

212. Mindfulness-based Therapy for people living with HIV

in people living with HIV. A recent RCT with 76 participants compared MBSR to participants on a wait list and found reduced frequency, severity and distress from symptoms resulting from anti-retroviral therapy (ARTs).(3) In addition, two small studies (one a RCT and one a pilot study) found that HIV positive participants receiving MBSR (2) or practicing mindfulness meditation (4) over the course of 8 weeks stabilized or increased their CD4 counts. Participants in the pilot study reported that group (...) Mindfulness-based Therapy for people living with HIV Rapid Review #56: May 2012 Mindfulness-based therapy for people living with HIV Question What is the use and benefit of mindfulness-based interventions for people living with HIV/AIDS? Key Take-Home Messages ? Findings from five systematic reviews evaluating mindfulness-based interventions (MBIs) -- specifically mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) – have found beneficial effects on mental

2012 Ontario HIV Treatment Network

213. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. (PubMed)

The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial. Hypertriglyceridemia is common in patients with HIV treated with highly active antiretroviral therapy (HAART).The goal of this study was to investigate the effect of the polyunsaturated fatty acids (PUFA) docosahexaenoic acid (DHA) 460 mg/eicosapentaenoic acid (EPA) 380 mg (...) on hypertriglyceridemia in HIV-treated patients.A double-blind, placebo-controlled, randomized, multicenter pilot study was undertaken in 48 evaluable HIV-infected patients undergoing HAART, with fasting triglyceride levels of 3.39 to 11.3 mmol/L. Patients were allowed fibrate or niacin but not statins and were randomized to PUFA 4 g daily versus placebo for 12 weeks. The primary end point was mean fasting triglyceride levels.The study included 48 patients; 23 in the PUFA group (mean age, 46.1 years) and 25

2012 Clinical therapeutics Controlled trial quality: predicted high

214. Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle (Full text)

Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycle HIV-1 DNA is found both integrated in the host chromosome and unintegrated in various forms: linear (DNAL) or circular (1-LTRc, 2-LTRc or products of auto-integration). Here, based on pre-established strategies, we extended and characterized in terms of sensitivity two methodologies for quantifying 1-LTRc and DNAL, respectively, the latter being able to discriminate between unprocessed or 3'-processed (...) that 3'-processing efficiency did not influence the total 2-LTRc accumulation although the nature of the LTR-LTR junction was qualitatively affected. Finally, a significant proportion of 1-LTRc was generated concomitantly with reverse transcription, although most of the 1-LTRc were produced in the nucleus.We describe the fate of viral DNA forms during HIV-1 infection. Our study reveals the interplay between various forms of the viral DNA genome, the distribution of which can be affected by mutations

2013 Retrovirology

215. Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting (Full text)

) guidelines, for the prevention of mother-to-child transmission of HIV, compared with a short-course of antiretroviral therapy (ART) for HIV-infected pregnant women. Interventions The WHO guidelines recommended a long course of triple ART for the mother, beginning at 14 weeks gestation and continuing until the end of breast feeding, plus ART for the infant, consisting of nevirapine daily for six weeks. This was compared with the minimum care in Nigeria, which was dual ART from 34 weeks gestation until one (...) week post-partum, including one dose of nevirapine for the infant and one for the mother upon delivery. This was the usual practice of short-course ART. Location/setting Nigeria/secondary care. Methods Analytical approach: A decision-tree model was developed to determine the cost-effectiveness of the prevention programmes, using published evidence. Three levels of coverage were modelled to provide estimates for: those receiving prevention at the time (10% of all pregnant HIV-infected women); those

2011 NHS Economic Evaluation Database.

216. Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention (Full text)

. The second was aimed at people in a high number of concurrent partnerships and aimed to reduce that number. The third aimed to reduce the number of partnerships for all those in more than one partnership. These were compared with no campaign. Location/setting Swaziland, Tanzania, Uganda, and Zambia/community care. Methods Analytical approach: A stochastic network model was developed to simulate the course of the HIV epidemic over 10 years. The perspective was not explicitly reported. Effectiveness data (...) Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention Enns EA, Brandeau ML, Igeme TK, Bendavid E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods

2011 NHS Economic Evaluation Database.

217. Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics???

Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? | BMJ EBM Spotlight by A recent BMJ analysis article argued that taking the “full course of antibiotics” is often likely counterproductive (see doi: 10.1136/bmj.j3418 )​. Details: –international health organizations and the WHO have pushed for completing antibiotic regimens: a 2016 WHO advisory to patients stated “always complete (...) the full prescription, even if you feel better, because stopping treatment early promotes the growth of drug-resistant bacteria”. The CDC has a similar message –the authors note that there is impressive evidence that some micro-organisms (eg TB, gonorrhea, HIV, S. typhi) can create spontaneous resistant mutations on treatment, and these mutants subsequently can be transmitted as resistant strains. [and there are good data supporting longer term therapies] –but many of the organisms with growing

2017 Evidence-Based Medicine blog

218. Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics???

Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? Primary Care Corner with Geoffrey Modest MD: Take the full course of antibiotics??? | BMJ EBM Spotlight by A recent BMJ analysis article argued that taking the “full course of antibiotics” is often likely counterproductive (see doi: 10.1136/bmj.j3418 )​. Details: –international health organizations and the WHO have pushed for completing antibiotic regimens: a 2016 WHO advisory to patients stated “always complete (...) the full prescription, even if you feel better, because stopping treatment early promotes the growth of drug-resistant bacteria”. The CDC has a similar message –the authors note that there is impressive evidence that some micro-organisms (eg TB, gonorrhea, HIV, S. typhi) can create spontaneous resistant mutations on treatment, and these mutants subsequently can be transmitted as resistant strains. [and there are good data supporting longer term therapies] –but many of the organisms with growing

2017 Evidence-Based Medicine blog

219. HIV-1 Group O Origin, Evolution, Pathogenesis, and Treatment: Unraveling the Complexity of an Outlier 25 Years Later. (PubMed)

HIV-1 Group O Origin, Evolution, Pathogenesis, and Treatment: Unraveling the Complexity of an Outlier 25 Years Later. Twenty-five years ago, an aberrant HIV-1 (now classified as HIV-1 group O) was described from a Cameroonian HIV patient living in Belgium. The epicenter of group O was later found to be in Central Africa, overlapping with the geographical location of the central chimpanzees (Pan troglodytes troglodytes) and western gorillas (Gorilla gorilla), the likely original hosts of group O (...) . Although the prevalence of group O has remained low at 1-2% in Cameroon, some European countries (France, Spain, Belgium) with strong colonial ties to Central Africa have reported the highest prevalence out of Africa. The sequence diversity between HIV-1 group O and M strains is huge, reaching 50 and 30% in the envelope and pol, respectively. This diversity has hindered diagnosis, monitoring, and treatment of group O-infected patients. Due to the intrinsic presence of the C181 mutation in group O, more

2017 AIDS reviews

220. The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age

The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results (...) information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>